Trials / Completed

CompletedNCT01888185

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's Disease

Status: Completed
Phase: —
Study type: Observational
Enrollment: 290 (actual)

Sponsor: Milton S. Hershey Medical Center · Academic / Other
Sex: All
Age: 21 Years – 90 Years
Healthy volunteers: Accepted

Summary

This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms \[conditions that are PD look-a-like diseases such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA)\] when combined with changes in certain proteins in body fluids that are related to iron (Fe).

Detailed description

The lack of in vivo biomarker(s) reflecting Parkinson's disease (PD)-related cell loss and associated pathoetiological/physiological processes in nigrostriatal structures has hindered discovery research and limited the ability to evaluate disease-modifying therapies. Recent research has generated excitement for using DTI and R2\* MRI measures as biomarker(s) for PD-related pathology in nigrostriatal pathways, but they fall short by the lack of understanding of their clinical implications and biological/pathological underpinnings. Working closely with the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP), the proposed work will investigate multimodal MRI techniques in combination with fluid-based iron (Fe) protein profiles to serve as in vivo markers for PD-related nigrostriatal pathology that can be used as biomarkers for diagnosing PD, following its progression, and gaining mechanistic understanding of PD pathoetiology and pathophysiology.

Conditions

Timeline

Start date: 2012-12-01
Primary completion: 2019-12-01
Completion: 2019-12-31
First posted: 2013-06-27
Last updated: 2020-01-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01888185. Inclusion in this directory is not an endorsement.